课题基金 / 基金详情

Highly active anti-retroviral therapy use during pregnancy and the risk of mother-to-child transmission, congenital malformation, and neonatal death

Highly active anti-retroviral therapy use during pregnancy and the risk of mother-to-child transmission, congenital malformation, and neonatal death
怀孕期间使用高效抗逆转录病毒治疗会增加母婴传播、先天畸形和新生儿死亡的风险
批准号:
288921
负责人:
Brard Anick
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Miscellaneous Programs
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-06-01 至 2014-06-01

项目摘要

项目成果

Brard Anick的其他基金

相似基金

相关文献

中文摘要
翻译
目前的数据表明,怀孕的艾滋病毒感染者应在怀孕期间接受治疗,以防止MCTC和新生儿死亡。然而,对于是否应该在妊娠早期(器官发生时)或晚期(器官发生时)开始治疗,目前还没有共识。
英文摘要
Present data suggest that pregnant HIV women should be treated during gestation to prevent MCTC and neonatal death. However, there is no consensus as to whether treatment should be initiated in the first trimester (when organogenesis occurs) or later (whe
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The CAnadian Mother-Child Initiative - knowledge mobilization from COnception to adulthood - CAMCCO-Outreach.
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform - SPOR Supplement
Canada Research Chair - Tier 1
  • 批准号:
    454003
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2021
  • 负责人:
    Brard Anick
  • 依托单位:
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform
海外基金